ECSP12012208A - Formulaciones orales y sales lipofílicas de metilnaltrexona - Google Patents

Formulaciones orales y sales lipofílicas de metilnaltrexona

Info

Publication number
ECSP12012208A
ECSP12012208A ECSP12012208A ECSP12012208A EC SP12012208 A ECSP12012208 A EC SP12012208A EC SP12012208 A ECSP12012208 A EC SP12012208A EC SP12012208 A ECSP12012208 A EC SP12012208A
Authority
EC
Ecuador
Prior art keywords
methylntrexone
lipophylic
salts
oral formulations
formulations
Prior art date
Application number
Other languages
English (en)
Inventor
Syed M Shah
Christopher Richard Diorio
Eric C Ehrnsperger
Xu Meng
Shareffi Kadum A Al
Jonathan Mare Cohen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of ECSP12012208A publication Critical patent/ECSP12012208A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Abstract

La presente invención proporciona composiciones que comprenden metilnaltrexona o una sal de ésta, y composiciones y formulaciones de ésta, para administración oral.
ECSP12012208 2010-03-11 2012-10-02 Formulaciones orales y sales lipofílicas de metilnaltrexona ECSP12012208A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
ECSP12012208A true ECSP12012208A (es) 2015-03-31

Family

ID=44148539

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012208 ECSP12012208A (es) 2010-03-11 2012-10-02 Formulaciones orales y sales lipofílicas de metilnaltrexona

Country Status (32)

Country Link
US (8) US8524276B2 (es)
EP (2) EP2371357B1 (es)
JP (4) JP6143409B2 (es)
KR (2) KR101913102B1 (es)
CN (2) CN107308125B (es)
AR (1) AR080491A1 (es)
AU (1) AU2011224275B2 (es)
BR (1) BR112012022873B1 (es)
CA (1) CA2789798C (es)
CL (1) CL2012002192A1 (es)
CO (1) CO6630134A2 (es)
CR (1) CR20120476A (es)
EA (1) EA029096B1 (es)
EC (1) ECSP12012208A (es)
ES (1) ES2623926T3 (es)
GE (1) GEP201606550B (es)
GT (1) GT201200247A (es)
HK (1) HK1245673A1 (es)
HU (1) HUE033133T2 (es)
IL (1) IL221452A (es)
MA (1) MA34146B1 (es)
MX (2) MX349145B (es)
MY (1) MY160727A (es)
NZ (3) NZ703564A (es)
PE (1) PE20130063A1 (es)
PL (2) PL2371357T3 (es)
SG (3) SG10201606618PA (es)
TN (1) TN2012000392A1 (es)
TW (2) TWI605814B (es)
UA (2) UA123856C2 (es)
WO (1) WO2011112816A1 (es)
ZA (1) ZA201808498B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
EP2164960A2 (en) 2007-05-25 2010-03-24 North Carolina State University Viral nanoparticle cell-targeted delivery platform
MX349145B (es) 2010-03-11 2017-07-14 Wyeth Llc * Formulaciones orales y sales lipofilicas de metilnaltrexona.
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
CN104254332A (zh) * 2011-12-19 2014-12-31 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007245A1 (en) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3718404A1 (en) 2014-10-17 2020-10-07 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progession
JP2022531685A (ja) * 2019-05-07 2022-07-08 バウシュ ヘルス アイルランド リミテッド メチルナルトレキソンの液体経口投与製剤
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
WO2021224138A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
WO1998035679A1 (de) 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
ATE493130T1 (de) * 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US20030022909A1 (en) 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
EP2939696B1 (en) 2001-10-18 2016-03-09 Nektar Therapeutics Polymer conjugates of opioid antagonists
EP1451174B1 (en) * 2001-11-29 2010-08-18 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
WO2003077867A2 (en) 2002-03-14 2003-09-25 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
AU2004229464A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20050004155A1 (en) 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
CA2532302C (en) * 2003-07-15 2016-12-20 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
KR20060111581A (ko) 2003-12-19 2006-10-27 쉐링 코포레이션 약제학적 조성물
JP2007517015A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
WO2006039705A2 (en) 2004-09-30 2006-04-13 Becton, Dickinson And Company Method for reducing or eliminating residue in a glass medical container and container made in accordance therewith
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
US8091568B2 (en) * 2006-08-16 2012-01-10 Novartis Ag Temporal photo-bleaching of colored lens care solutions and use thereof
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
MX2009010515A (es) * 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
AU2008233133B2 (en) * 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
EA201001643A1 (ru) * 2008-05-07 2011-06-30 Нектар Терапеутикс Пероральное введение периферически действующих опиоидных антагонистов
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
MX349145B (es) 2010-03-11 2017-07-14 Wyeth Llc * Formulaciones orales y sales lipofilicas de metilnaltrexona.
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
HK1245673A1 (zh) 2018-08-31
PE20130063A1 (es) 2013-02-11
EP2371357A1 (en) 2011-10-05
US10307417B2 (en) 2019-06-04
TW201622724A (zh) 2016-07-01
MX2012009125A (es) 2012-09-07
AU2011224275A1 (en) 2012-08-23
PL2371357T3 (pl) 2017-09-29
CN107308125B (zh) 2021-07-16
GEP201606550B (en) 2016-10-10
US20190117645A1 (en) 2019-04-25
CN102918039A (zh) 2013-02-06
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
IL221452A (en) 2017-07-31
US20140249171A1 (en) 2014-09-04
US10507206B2 (en) 2019-12-17
JP2019034958A (ja) 2019-03-07
CL2012002192A1 (es) 2012-09-28
US10376505B2 (en) 2019-08-13
SG10201606618PA (en) 2016-09-29
TW201141479A (en) 2011-12-01
MY160727A (en) 2017-03-15
US20190314365A1 (en) 2019-10-17
CA2789798C (en) 2020-09-22
US20200121673A1 (en) 2020-04-23
CN107308125A (zh) 2017-11-03
UA111717C2 (uk) 2016-06-10
EA029096B1 (ru) 2018-02-28
ZA201808498B (en) 2019-08-28
NZ703564A (en) 2016-08-26
NZ601595A (en) 2015-01-30
CR20120476A (es) 2012-11-30
JP6429955B2 (ja) 2018-11-28
JP2011190259A (ja) 2011-09-29
BR112012022873A2 (pt) 2016-08-30
SG183133A1 (en) 2012-09-27
GT201200247A (es) 2013-09-11
JP2016029054A (ja) 2016-03-03
ES2623926T3 (es) 2017-07-12
US8524276B2 (en) 2013-09-03
WO2011112816A1 (en) 2011-09-15
US20130330407A1 (en) 2013-12-12
TWI605814B (zh) 2017-11-21
TWI589293B (zh) 2017-07-01
CO6630134A2 (es) 2013-03-01
HUE033133T2 (en) 2017-11-28
UA123856C2 (uk) 2021-06-16
US20160206612A1 (en) 2016-07-21
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
CN102918039B (zh) 2017-06-09
NZ702826A (en) 2016-08-26
AR080491A1 (es) 2012-04-11
MA34146B1 (fr) 2013-04-03
KR101913102B1 (ko) 2018-10-31
EP2371357B1 (en) 2017-02-01
MX349145B (es) 2017-07-14
EP3178472B1 (en) 2021-10-27
BR112012022873B1 (pt) 2021-09-14
EP3178472A1 (en) 2017-06-14
MX368805B (es) 2019-10-17
JP6647368B2 (ja) 2020-02-14
KR101982482B1 (ko) 2019-05-27
JP2017206553A (ja) 2017-11-24
SG10201501821RA (en) 2015-05-28
US9314461B2 (en) 2016-04-19
TN2012000392A1 (en) 2014-01-30
IL221452A0 (en) 2012-10-31
US20120070495A1 (en) 2012-03-22
EA201270741A1 (ru) 2013-02-28
US20190117646A1 (en) 2019-04-25
US8956651B2 (en) 2015-02-17
KR20130010900A (ko) 2013-01-29
JP6143409B2 (ja) 2017-06-07

Similar Documents

Publication Publication Date Title
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
CO7091182A2 (es) Inhibidores de beta-lactamasa isoxazol
HN2011003371A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
CR20130406A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
ECSP11011391A (es) Métodos y productos intermedios para preparar agentes farmacéuticos
CR20110110A (es) Composicion farmaceutica
CL2011000482S1 (es) Aplicador para cuidado oral.
CR10505A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
BR112013008601A2 (pt) formulações de emulsão de clevidipina contendo agentes antimicrobianos
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
AR102203A1 (es) Composiciones para el cuidado oral que comprenden zinc, arginina y serina
CO6650346A2 (es) Composiciones de tetraciclina
MX344473B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
BR112013019518A2 (pt) composições para cuidado oral.
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
BR112013015986A2 (pt) composições para cuidados orais.
CO6720980A2 (es) Composiciones bucales
ITTO20111220A1 (it) Composizione contenente un fosfato di tocoferolo e procedimento di preparazione.
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
BR112015004115A2 (pt) composições farmacêuticas compreendendo flurbiprofeno
BR112015012824A2 (pt) composições e métodos para tratar cáries dentárias
DOP2008000071A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden